David Sandler, MD
Clinical Cardiac Electrophysiology · Tulsa, OKNPI 1619947124
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Boston Scientific at 40.7% of the total. Reporting peaked in 2019 at $39,890 and has fallen 64.0% since, to $14,378 in 2025.
Across 400 payments — averaging $214.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$35K
- Pfizer$22K
- Johnson & Johnson$11K
- E.r. Squibb & Sons, L.L.C.$8K
- Biosense Webster, Inc.$3K
- Abbott$2K
- plus $6K from 16 others
Across 42 payments — averaging $4038.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$115K
- Boston Scientific$54K
- Medtronic$190
What the payments were for
- Consulting fees$19,53823%
- Speaking & faculty fees$50,06158%
- Travel & lodging$4,6845%
- Food & beverage$11,51413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 138 | $34,949 |
| Pfizer | 32 | $21,899 |
| Johnson & Johnson | 15 | $10,766 |
| E.r. Squibb & Sons, L.L.C. | 20 | $7,617 |
| Biosense Webster, Inc. | 75 | $2,550 |
| Abbott | 59 | $2,493 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $2,423 |
| Medical Device Business Services, Inc. | 2 | $767 |
| Medtronic | 12 | $637 |
| ZOLL Respicardia, Inc. | 2 | $386 |
| Atricure, Inc. | 3 | $350 |
| Abiomed | 4 | $335 |
| Philips North America LLC | 7 | $236 |
| Novartis | 6 | $97 |
| Cardiva Medical, Inc. | 3 | $75 |
| Irhythm Technologies, Inc. | 4 | $74 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 2 | $29 |
| Altathera Pharmaceuticals LLC | 1 | $29 |
| Baxter Healthcare | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$28,894
- GENERAL - THERAPIES$17,974
- XARELTO$10,500
- GENERAL EP$10,156
- LifeVest$2,250
- Carto 3$1,242
- AVEIR$1,031
- Carto 3 System$767
- WATCHMAN Access System$639
- remede System$386
- Watchman$341
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$281
- WATCHMAN FLX$251
- Impella$228
- Accent Pacemaker$144
- Micra$141
- Quadra Assura CRT Defibrillator$140
- Ensite Cardiac Mapping System$113
- Confirm Rx$106
How this compares
$85,796 in reported general payments places this provider in the 85th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
See all clinical cardiac electrophysiology providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,082 | $999,003 |
| XareltoRivaroxaban | 106 | $110,232 |
| MultaqDronedarone Hcl | 33 | $37,966 |
| EntrestoSacubitril/Valsartan | 28 | $31,827 |
| CorlanorIvabradine Hcl | 13 | $16,527 |
| Flecainide Acetate | 263 | $11,412 |
| Metoprolol Succinate | 353 | $5,851 |
| Dofetilide | 27 | $5,414 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 29 | $4,733 |
| Amiodarone Hcl | 223 | $3,147 |
| Metoprolol Tartrate | 227 | $1,776 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 60 | $1,576 |
| Ranolazine ErRanolazine | 17 | $1,195 |
| SotalolSotalol Hcl | 37 | $1,049 |
| Losartan Potassium | 64 | $830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $21,899 | $999,0031,082 claims |
| Johnson & JohnsonXarelto | $10,766 | $110,232106 claims |
| Sanofi-aventis U.S. LLCMultaq | $35 | $37,96633 claims |
| NovartisEntresto | $97 | $31,82728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
Other clinical cardiac electrophysiology in Tulsa
- Craig CameronTulsa$52K
- Vikram KatariTulsa$34K
- Venkatesh RaviTulsa$31K
- James ComanTulsa$24K
- Joseph GardTulsa$23K
- Ele WuTulsa$22K
- Andrew HinojosTulsa$17K
- David OkadaTulsa$16K
- Warren JackmanOklahoma City$2.3M
- Sunny PoOklahoma City$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.